BioreclamationIVT, which is backed by Arsenal Capital Partners, has acquired TransCell Science, a provider of research and development services for industry and academia. No financial terms were disclosed.
WESTBURY, N.Y., March 9, 2017 /PRNewswire/ — BioreclamationIVT has acquired TransCell Science, a privately held contract research organization (CRO) specializing in the use of primary cells for phenotypic screening assays. With its scientific expertise in the areas of cell culture and cell-based assays, clients have looked to TransCell as a partner in developing protocols and conducting studies that provide pertinent data for their research programs. The output from such studies enables “go” or “no go” decisions with a higher level of confidence at a much earlier time point within the drug discovery process and greatly reduces the chance of downstream failure.
Through prior acquisitions and organic growth, BioreclamationIVT has become the premier supplier of biological specimens to the life sciences industry. “We have enormous respect for what TransCell Science has accomplished since their founding in 2011,” said Jeff Gatz, BioreclamationIVT CEO. “Building upon our collective synergies, this transaction positions us to accelerate growth and unleash the full potential of our merged companies. Together, BioreclamationIVT and TransCell Science will form a complete solution spanning biospecimen acquisition to use of those samples within highly relevant in vitro assays.”
BioreclamationIVT is backed by Arsenal Capital Partners, a leading investor in healthcare and life sciences companies managing approximately $3 billion of capital. “We are excited to extend BioreclamationIVT’s leadership position in providing biological products and services necessary for efficient development of new drugs and diagnostics, especially targeted therapeutics,” said David Spaight, Arsenal Capital Operating Partner and Chairman of BioreclamationIVT. “TransCell Science aligns with Arsenal’s focused M&A program targeting leaders in biological products and complementary services.”
Dr. Chris Hansis, TransCell Science Founder and CEO, will join the BioreclamationIVT executive team as Chief Scientific Officer. “TransCell has been a trusted research partner for top pharmaceutical, biotech and multinational personal care products companies and leading academic and government institutions, and I couldn’t be prouder of our achievements to date,” said Hansis. “We have capitalized on growing pressure within the industry to outsource research activities and I am particularly eager to extend our momentum through this transaction.”
BioreclamationIVT’s family of products and services are unified by one goal: to provide researchers with the best tools and information for making a difference in people’s lives. “We’re excited by the opportunity this affords us to work more intimately with our clients in the scientific community as they develop their research programs,” said Gatz. “We expect the expansion of our service offerings will help to speed up the drug discovery process and ensure efficacious therapeutics get to patients that need them most.”
About TransCell Science
TransCell Science is a provider of innovative research and development services to industry and academia. TCS specializes in novel drug and biologics assays based on human primary cells grown from explant tissue; this technology constitutes the most accurate disease models which surpass cell lines, organ culture or animal models. TCS custom develops and manages complex and technologically challenging projects for pharmaceutical, personal care companies, and leading academic and government institutions. By constantly adopting new technologies, TCS strives to stay at the forefront of cell culture and drug assay science.
BioreclamationIVT is a worldwide provider of biological products to the life sciences and pharmaceutical industries. BioreclamationIVT specializes in control and disease state matrices manufactured from human and animal biological specimens and has recently expanded their offering to include cell processing and phenotypic screening services. This portfolio of products is utilized throughout the drug discovery and development research workflows, and directly supports the personalized medicine initiative by coupling clinical information with numerous disease state fluids and tissues. Its reputation within the industry for providing exceptional customer service coupled with the highest quality specimens and services has made it the first choice supplier for biospecimens for over 35 years.
About Arsenal Capital Partners
Established in 2000, Arsenal Capital Partners is a leading New York based private equity firm that specializes in investments in middle market specialty industrials and healthcare companies. Since inception, Arsenal has raised institutional equity investment funds of approximately $3 billion. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value-add. For additional information on Arsenal Capital Partners, please visit. www.arsenalcapital.com.